Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact.
Abstract
Background
Immune checkpoint inhibitors (ICIs) have transformed outcomes in advanced melanoma, but optimal treatment duration remains unclear. Most patients are treated until two years, treatment limiting toxicity (TLT), or progression. This study evaluates real-world outcomes after elective discontinuation of ICIs following treatment response based on national recommendations.
Methods
Data from the Danish Metastatic Melanoma Database (DAMMED) were retrieved on all patients who initiated first-line ICI therapy (anti-PD1 +/- anti-CTLA4) between January 2019 and July 2023. All patients who discontinued treatment after a maximum of 18-months due to complete response (CR) or partial response (PR) were included while patients stopping due to progression, TLT or other causes were excluded.
Results
In total, 163 patients were included (63% male, median age 71 [33-91]). Most had cutaneous melanoma (85%), M1c disease (42%), and received anti-PD1 (80%). Overall, 82 and 81 patients discontinued following CR and PR, respectively. Median and minimum treatment duration was 8.1/7.1 months (CR), and 11.1/8.9 months (PR). The median follow-up was 48 months [IQR: 34.6-60.1]. At 12- and 36-months, PFS was 100%/87% (CR), and 96%/81% (PR). At 12- and 36- months, OS was 99%/98% (CR) and 100%/87% (PR). Melanoma-specific survival (MSS) at 12- and 36 months was 100%/99% (CR) and 100%/93% (PR).
Conclusion
Early discontinuation following an objective response is associated with an excellent 3-year MSS and a potential significant reduction in treatment expenses. These findings suggest that, in selected responding patients, treatment discontinuation before the 2-year landmark may be feasible without compromising outcomes, supporting response-guided discontinuation strategies.